Plain-English translation of NCT04499898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a blood pressure medication called can prevent dangerous bleeding in people with cirrhosis (severe liver disease) and high blood pressure. Right now, doctors use a procedure called band ligation—where a small band is placed around enlarged blood vessels in the esophagus—to prevent this bleeding. This study compares the medication to the procedure to see which approach works better.
People with advanced liver disease can develop life-threatening bleeding from enlarged blood vessels in the esophagus, and this is a serious complication. Researchers want to find out if this medication, which is already used safely for heart and blood pressure conditions, could be a simpler alternative to the current procedure for preventing this dangerous bleeding.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either take the medication daily or receive the preventive procedure. You'll have regular follow-up visits where doctors will check how well your treatment is working and watch for any side effects. The study will track whether either approach successfully prevents bleeding over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Egypt
Phase
Large-scale testing
Sponsor
Sherief Abd-Elsalam
Enrollment target
~306 participants
Started
October 2018
Primary completion
December 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2020.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sherief Abd-Elsalam, ass. prof.
Tanta University - Faculty of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.